Annual surveys take pulse of executive management, DTC marketers; what’s your favorite social media?
Cegedim-Dendrite (Bedminster, NJ) has released a pair of its annual surveys measuring business actions and moods among pharma marketers and executives dealing with market access and DTC issues. While there are many data points on specific tactics and actions, the summary direction seems to be: staying abreast of a changing commercial model, and focusing on holding onto existing customers (patients) and relationships in its DTC methods.
In one survey of top pharma management in North and South America, Cegedim-Dendrite found that commercial business models are the No. 1 concern as “the big issue keeping you up at night,”—outdistancing pipeline growth, regulatory reform or generic competition. And the key element within the business model is “increased focus in market access strategies,” which was mentioned by twice as many executives as those who mentioned “primary sales force realignment” or physician-directed marketing activities. (A third Cegedim-Dendrite survey, of European pharma managers, indicates that companies there, by a 70% majority have already begun changing their messaging “in response to the need to demonstrate ROI to health providers.”)
The annual “DTC Check-Up” survey, conducted among manufacturers, consultants, agencies and other vendors, find that DTC spending is expected to rise significantly this year, especially in comparison to last year’s generally dour outlook. Four in ten marketers expect an increase, and the combination of “increase” and “stay the same” is at 72%, as compared to 43% in 2009. Generally, spending on television, direct mail, print and radio advertising will fall, while website spending, relationship marketing, adherence programs and e-mail campaigns will increase. “This mixture shows that DTC marketers are continuing in their aim to build and maintain long-term relationships with their customers,” says Cegedim-Dendrite.
One interesting result of the executive survey is their personal use of social media. When asked which media are used on a daily basis, the results were:
Even so, the majority (51%) of respondents say that their company’s investment in social media is less than 5% of overall marketing budgets.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.